Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Seong-Keun, Chowell, Diego, Valero, Cristina, Morris, Luc G. T., Chan, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990074/
https://www.ncbi.nlm.nih.gov/pubmed/35393553
http://dx.doi.org/10.1038/s41698-022-00267-7
Descripción
Sumario:The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.

Ejemplares similares